Menu Search
Equities

Coherus BioSciences Inc

8C5:BER

Coherus BioSciences Inc

Actions
  • Price (EUR)1.03
  • Today's Change-0.042 / -3.93%
  • Shares traded6.00k
  • 1 Year change-43.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 20:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.

  • Revenue in USD (TTM)304.34m
  • Net income in USD-450.00k
  • Incorporated2010
  • Employees235.00
  • Location
    Coherus BioSciences IncC/O DENNIS M. LANFEAR201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY 94065United StatesUSA
  • Phone+1 (650) 649-3530
  • Fax+1 (302) 655-5049
  • Websitehttps://www.coherus.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.